List of Addyi drug patents
Addyi is owned by Sprout Pharms.
Addyi contains Flibanserin.
Addyi has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Addyi are:
- US9468639
- US7420057
Addyi was authorised for market use on 18 August, 2015.
Addyi is available in tablet;oral dosage forms.
Addyi can be used as use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd).
The generics of Addyi are possible to be released after 09 May, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7420057 | SPROUT PHARMS | Stable polymorph of flibanserin |
Aug, 2022
(7 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9468639 | SPROUT PHARMS | Treating sexual desire disorders with flibanserin |
Oct, 2022
(5 months ago) | |
| US8227471 | SPROUT PHARMS | Treating sexual desire disorders with flibanserin |
May, 2023
(a month from now) | |
| US7151103 | SPROUT PHARMS | Method of treating female hypoactive sexual desire disorder with flibanserin |
May, 2028
(5 years from now) | |
Drugs and Companies using FLIBANSERIN ingredient
Market Authorisation Date: 18 August, 2015
Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)
Dosage: TABLET;ORAL
ADDYI family patents
23
United States
10
European Union
5
China
4
Brazil
4
Argentina
4
Korea, Republic of
4
Japan
2
Portugal
2
Germany
2
Malaysia
2
Spain
2
Croatia
2
New Zealand
2
Norway
2
Mexico
2
Austria
2
EA
2
South Africa
2
Canada
2
Hungary
2
Slovenia
2
Yugoslavia
2
Ukraine
2
Israel
2
Poland
2
Australia
2
Ecuador
2
Denmark
1
Colombia
1
Hong Kong
1
ME
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic